Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
TP53 wild-type ALRN-6924 Merkel cell carcinoma predicted - sensitive detail...
RB1 loss LY3295668 Merkel cell carcinoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02036476 Phase II Cabozantinib Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma Terminated USA 0
NCT02155647 Phase II Avelumab Avelumab in Subjects With Merkel Cell Carcinoma (JAVELIN Merkel 200) Completed USA | ITA | FRA | ESP | DEU | AUS 1
NCT02267603 Phase II Pembrolizumab Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer Completed USA 0
NCT02488759 Phase Ib/II Nivolumab A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358) Completed USA | NLD | GBR | FRA | ESP | DEU | BEL 4
NCT02514824 Phase Ib/II Sapanisertib MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma Completed USA 0
NCT02584829 Phase Ib/II IFN-B Avelumab Localized Radiation Therapy or Recombinant Interferon Beta and MSB0010718C With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma Terminated USA 0
NCT02643303 Phase Ib/II Durvalumab + Poly ICLC Tremelimumab A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers Completed USA 0
NCT02819843 Phase II Talimogene laherparepvec A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors Completed USA 0
NCT02831179 Phase I Capecitabine + Temozolomide + Veliparib Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Withdrawn 0
NCT02936323 Phase Ib/II PEN-221 PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers Completed USA | GBR 0
NCT02978625 Phase II Nivolumab + Talimogene laherparepvec Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Active, not recruiting USA 0
NCT03071406 Phase II Ipilimumab + Nivolumab Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma Active, not recruiting USA 0
NCT03074513 Phase II Atezolizumab + Bevacizumab Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors Active, not recruiting USA 0
NCT03212404 Phase I Cosibelimab Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers Recruiting NZL | FRA | ESP | AUS 5
NCT03271372 Phase III Avelumab Adjuvant Avelumab in Merkel Cell Cancer (ADAM) Active, not recruiting USA 0
NCT03304639 Phase II Pembrolizumab Pembrolizumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Merkel Cell Cancer Active, not recruiting USA 0
NCT03416335 Phase Ib/II DSP-0509 DSP-0509 + Pembrolizumab A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile Terminated USA 0
NCT03435640 Phase Ib/II NKTR-214 + NKTR-262 Nivolumab + NKTR-214 + NKTR-262 A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies Terminated USA 0
NCT03538028 Phase I INCAGN02385 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Completed USA 0
NCT03590054 Phase I Abexinostat + Pembrolizumab Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies Completed USA 0
NCT03599713 Phase II Retifanlimab A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 4
NCT03628677 Phase I AB154 AB154 + Zimberelimab A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies Active, not recruiting USA | AUS 0
NCT03629756 Phase I Etrumadenant + Zimberelimab A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies Completed USA | AUS 0
NCT03712605 Phase III Pembrolizumab Pembrolizumab Compared to Standard of Care Observation in Treating Patients With Completely Resected Stage I-III Merkel Cell Cancer Active, not recruiting USA 0
NCT03747484 Phase Ib/II Avelumab + FH-MCVA2TCR Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer Active, not recruiting USA 0
NCT03767348 Phase Ib/II Nivolumab + RP1 RP1 Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) Recruiting USA | GBR | FRA | ESP | DEU 0
NCT03783078 Phase III Pembrolizumab Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913) Completed USA | NZL | ITA | FRA | ESP | CAN | AUS 1
NCT03787602 Phase Ib/II Avelumab + KRT-232 KRT-232 Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma Recruiting USA | NLD | ITA | FRA | ESP | DEU | CAN | AUS 2
NCT03798639 Phase I Ipilimumab + Nivolumab Nivolumab Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer Completed USA 0
NCT03816332 Phase I Ipilimumab + Nivolumab + Prednisone + Tacrolimus Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers Active, not recruiting USA 0
NCT03816345 Phase I Nivolumab Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer Recruiting USA | CAN 0
NCT03853317 Phase II Avelumab + haNK cells + Nogapendekin alfa inbakicept Evaluate Efficacy of Avelumab, haNK and N-803 in Subjects With Progressed MCC on or After Checkpoint Inhibitor Therapy. Terminated USA 0
NCT03901573 Phase Ib/II Atezolizumab + NT-I7 High-Risk Skin Cancers With Atezolizumab Plus NT-I7 Terminated USA 0
NCT03936959 Phase I LY3434172 A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer Completed USA | FRA | BEL | AUS 1
NCT03988647 Phase II Pembrolizumab Phase II Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinoma Terminated USA 0
NCT04096638 Phase I Nivolumab + SB 11285 SB 11285 Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors Recruiting USA 0
NCT04160065 Phase I IFx-Hu2.0 Immunotherapy With IFx-Hu2.0 Vaccine for Advanced MCC or cSCC Active, not recruiting USA 0
NCT04260802 Phase Ib/II OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001 A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers Recruiting CAN 0
NCT04261855 Phase Ib/II Avelumab Avelumab + lutetium Lu 177 dotatate Targeted Therapy and Avelumab in Merkel Cell Carcinoma (GoTHAM) Recruiting AUS 0
NCT04291885 Phase II Avelumab Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma (I-MAT) Recruiting NZL | AUS 0
NCT04393753 Phase II Avelumab + Domatinostat Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1 (MERKLIN2) Completed NLD | ITA | FRA | ESP | DEU | BEL 0
NCT04423029 Phase Ib/II DF6002 DF6002 + Nivolumab A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting USA | FRA | ESP | AUS 0
NCT04521413 Phase Ib/II CFI-402411 + Pembrolizumab CFI-402411 Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies Recruiting USA | CAN 1
NCT04590781 Phase Ib/II Pembrolizumab + XmAb18087 XmAb18087 Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer Terminated USA 0
NCT04725331 Phase Ib/II BT-001 BT-001 + Pembrolizumab A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors Recruiting FRA | BEL 0
NCT04787042 Phase Ib/II Pembrolizumab + ST-067 ST-067 Obinutuzumab + ST-067 Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 Active, not recruiting USA 0
NCT04792073 Phase II Avelumab Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma Recruiting USA 0
NCT04819373 Phase II BDB001 BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors Completed USA 0
NCT04869137 Phase II Lenvatinib + Pembrolizumab Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma Recruiting USA 0
NCT04874831 Phase II Avelumab + Domatinostat Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1) Withdrawn 0
NCT04902040 Phase Ib/II Atezolizumab + Avelumab + Durvalumab + Nivolumab + Pembrolizumab + Plinabulin Atezolizumab + Avelumab + Durvalumab + Nivolumab + Pembrolizumab Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies Recruiting USA 0
NCT04902443 Phase I Nivolumab + Pomalidomide Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV Recruiting USA 0
NCT04916002 Phase II Cemiplimab + Vidutolimod CMP-001 in Combination With IV PD-1-Blocking Antibody in Subjects With Certain Types of Advanced or Metastatic Cancer Suspended USA | AUS 0
NCT04975152 Phase I Cemiplimab Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma Recruiting USA 0
NCT05076760 Phase I MEM-288 Study of MEM-288 Oncolytic Virus in Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC) Recruiting USA 0
NCT05086692 Phase Ib/II MDNA11 + Pembrolizumab A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1) Recruiting USA | CAN | AUS 1
NCT05120271 Phase Ib/II BOXR1030 BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors (DUET-1) Recruiting USA 0
NCT05199272 Phase Ib/II 23ME-00610 A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies Active, not recruiting USA | CAN 0
NCT05269381 Phase I Cyclophosphamide + Neoantigen peptide vaccine + Pembrolizumab + Sargramostim Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (PNeoVCA) Recruiting USA 0
NCT05329792 Phase II Daromun L19IL2/L19TNF in Skin Cancer Patients Recruiting ITA | FRA | ESP 0
NCT05422781 Phase I ITI-3000 Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC) Completed USA 0
NCT05496036 Phase II Pembrolizumab Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma (MCC) Recruiting USA 0
NCT05583708 Phase II lutetium Lu 177 dotatate + Pembrolizumab Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer (iPRRT) Suspended USA 0
NCT05594290 Phase II Cisplatin + Etoposide + Retifanlimab Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery (MERCURY) Recruiting ITA 0
NCT05859074 Phase I MQ710 + Pembrolizumab MQ710 A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer Active, not recruiting USA 0
NCT05896839 Phase Ib/II Ipilimumab + Nivolumab + Prednisone + Sirolimus Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer Recruiting USA 0
NCT05904496 Phase I BGB-30813 BGB-30813 + Tislelizumab A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-30813 Active, not recruiting USA | ESP | AUS 0
NCT05947500 Phase II M1774 Avelumab + M1774 Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial Recruiting USA 0
NCT06014086 Phase I PH-762 Intratumoral PH-762 for Cutaneous Carcinoma Recruiting USA 0
NCT06021626 Phase I CRD3874 A Study of CRD3874-SI in People With Sarcoma or Merkel Cell Cancer Recruiting USA 0
NCT06047379 Phase Ib/II NEO212 NEO212 + Regorafenib Carboplatin + NEO212 + Paclitaxel Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NEO212 Ipilimumab + NEO212 NEO212 + Pembrolizumab NEO212 + Nivolumab Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis Recruiting USA 0
NCT06056895 Phase II INCAGN02385 + INCAGN02390 + Retifanlimab Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma (TRICK-MCC) Recruiting USA 0
NCT06086288 Phase II Pembrolizumab Cisplatin + Etoposide + Pembrolizumab Carboplatin + Etoposide + Pembrolizumab Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in Treatment naive Advanced meRkel Cell cArcinoma (MCC) (PANDORA) Not yet recruiting ITA 0
NCT06151236 Phase II Nivolumab + Relatlimab Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma Recruiting AUS 0